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Alveolar eosinophilia in current
smokers with chronic obstructive 
pulmonary disease in the SPIRO-
MICS cohortTo the Editor:
Novel therapies for chronic obstructive pulmonary disease 
(COPD) are urgently needed. Eosinophilic inflammation is an 
appealing target, because blood or sputum eosinophils in stable 
COPD may predict responses to systemic or inhaled corticoste-
roid therapy.1 Titrating steroid therapy in the stable state on the 
basis of sputum eosinophils reduced severe exacerbations2 and 
has been recommended for clinical practice.3 However, the prev-
alence of eosinophilic inflammation in COPD and its uniformity 
between systemic and lung compartments remain incompletely 
defined. Controversy exists on whether sputum analysis (reflect-
ing large airway events) is required, or whether blood eosino-
philia can suffice, on the basis of strong correlation between the 
2 found by 1 group.4 Thus, better understanding of eosinophils 
in COPD is needed.
The Subpopulations and Intermediate Outcomes in COPD 
Study (SPIROMICS) (ClinicalTrials.gov NCT01969344T4),which recently completed enrolling 2981 participants, provides
a unique opportunity to address these controversies.5 This anal-
ysis was performed on a subset (n5 139) of SPIROMICS partic-
ipants who agreed to a bronchoscopy substudy that used
multicolor flow cytometry to identify leukocyte subsets and to
define their activation states. All investigations were conducted
according to the principles of the Declaration of Helsinki. The
protocol was approved by the institutional review boards of the
8 participating clinical centers. Briefly, participants underwent
sputum induction, then 2 to 4weeks later, returned for a bronchos-
copy visit at which we collected peripheral blood and bronchoal-
veolar lavage (BAL). Sputum, blood, and BAL samples were
stained on the day of collection at the clinical centers, then fixed
and shipped to a central laboratory for flow cytometry analysis.
Additional details can be found in this article’s Online Repository
at www.jacionline.org. We categorized participants as never-
smokers (NS), current smokers (CS-NAO) and former smokers
(FS-NAO) with no airflow obstruction, and current smokers
(CS-COPD) and former smokers (FS-COPD) with COPD
(Table I).
Using our described staining protocol and flow cytometric
gating,6 we identified eosinophils as CD451, CCR31, CD162
cells with high forward scatter and side scatter (see Fig E1 in
this article’s Online Repository at www.jacionline.org). When
grouping subjects by smoking status and COPD disease status,
we found no differences between eosinophil percentages in pe-
ripheral blood (Fig 1, A) or sputum (Fig 1, B). In contrast, BAL
eosinophils were significantly increased as a percentage of all
CD45 1 cells in current smokers with COPD, relative to other
groups (Fig 1, C). However, the percentage of BAL eosinophils
did not correlate significantly in any sample type with FEV1%
predicted or imaging variables (percent emphysema or Pi10)
(not shown). IgE levels were largely within the normal range
(geometric mean, 46.7 IU/mL; 95% CI, 35.3-60.2). Log10-trans-
formed IgE levels neither differed between groups nor correlated
with eosinophil percentages in any of the 3 sample types, whether
among all subjects or only the CS-COPD group (not shown). We
found no correlation of BAL eosinophil percentages with plasma
levels of the CCR3 ligands CCL5, CCL8, and CCL24 (not
shown), and did not measure CCL11 or IL-5.
To better understand the correlation between current smoking
and elevated BAL eosinophil percentages in COPD, we per-
formed multivariate modeling. We adjusted for demographic
characteristics (age, sex, black race), smoking intensity (per 10
pack-year exposure), obstruction and smoking status (never vs
former vs current), chronic bronchitis, histories of asthma or
gastroesophageal reflux, and inhaled corticosteroid use. We also
controlled for the presence of self-reported eye/nose allergies
(defined as both any diagnosis and current diagnosis, with positive
response [presence of allergy symptoms] reported by 18.5% of
participants) and self-reported seasonal allergies (positive
response [presence of allergy symptoms] reported by 13.3% of
participants). Results showed a significant association between
eosinophil percentage in BAL with current smoking plus COPD,
with a 2.5-fold increase in eosinophil percentage in smokers with
COPD (b 5 2.5; 95% CI, 1.0-3.9).
To gain insights into eosinophil activation states in various
compartments, we examined cell-surface expression of the
adhesion molecules CD11b (Clone CBRM1/5, which recognizes
an activation-specific epitope), CD34, and CD49d; the activation
receptor CD69; and CD125, the IL-5 receptor alpha chain.Within
TABLE I. Subjects’ characteristics
Group NS FS-NAO CS-NAO FS-COPD CS-COPD P value
Subjects, n 21 29 30 37 22
Sex ratio, M/F 8/13 13/16 16/14 24/13 12/10 .32
Age (y) 52 6 8 63 6 8 51 6 6 65 6 7 60 6 7 <.0001
Smoking (pack-years) 0 6 0 39 6 16 35 6 12 51 6 24 53 6 20 .0007*
FEV1 (% predicted) 100 6 0 102 6 12 97 6 13 79 6 19 78 6 17 <.0001
FEV1/FVC 0.82 (0.06) 0.76 (0.06) 0.76 (0.05) 0.58 (0.09) 0.58 (0.10) <.0001
ICS use (yes/no) 1/20 1/28 3/26 15/22 6/16 .0002
Data are presented as mean 6 SD except for sex ratios and ICS use; former smoker defined as having quit for more than 6 mo. One-way ANOVAwith Holm-Sidak post hoc testing
was used to determine significant differences between groups.
ICS, Inhaled corticosteroid; F, female; M, male.
*The NS group omitted, no single group statistically different by post hoc testing.
Data missing from 1 subject.
FIG 1. Active smoking significantly increases BAL eosinophil percentages in
COPD. Flow cytometric analysis of eosinophils in blood (n 5 97) (A), sputum
(n 5 94) (B), and BAL (n 5 91) (C). Box and whiskers plot showing
median6 interquartile range and5th and 95th percentiles,with outliers shown
as symbols. *P < .05; **P < .01; ANOVA with Holm-Sidak post hoc testing.a given subject group, every receptor showed significant differ-
ences between sample types in percentages of positive eosino-
phils (see Table E1, column P values, in this article’s Online
Repository at www.jacionline.org). In contrast, within sample
types, only CD125 in BAL differed between groups (significantly
lower in CS-COPD) (Table E1, row P values).
Accordingly, we analyzed eosinophil receptor-positivity in the
3 sample types regardless of subject groups (see Fig E2 in this ar-
ticle’s Online Repository at www.jacionline.org). Relative to
blood, significantly more eosinophils were positive for CD11b,
CD34, and CD69 in BAL and for CD34 and CD69 in sputum.
CD69 may contribute to intrapulmonary eosinophil retention as
shown for lung-resident T memory cells,7 although for both cell
types, CD69 might be upregulated by the lung environment but
not causing retention.
Finally, we examined the magnitude of receptor expression by
mean fluorescence intensity (see Table E2 and Fig E3, A, in this
article’s Online Repository at www.jacionline.org), which, as
with the percent of eosinophils expressing a receptor, differed
significantly between sample types for every receptor. In terms
of subject comparisons, there were no significant differences in
the expression of CD34, CD69, or CD125 by BAL eosinophils,
but the expression of CD11b was significantly greater in FS-
NAO relative to FS-COPD (Fig E3, B). Moreover, the expression
of CD49d was significantly higher in BAL eosinophils of CS-
COPD than in groups other than CS-NAO, which was also
elevated relative to FS-COPD (but not to other groups)
(Fig E3, B).
This analysis demonstrates that active smoking increases
steady-state localization of eosinophils to the distal lung in
COPD, relative to smokers (current or former) without airflow
obstruction and to NS. This interaction was not observed in FS-
COPD, implying that smoking reversibly impacts eosinophil
recruitment or retention (or both). Eosinophilic inflammation was
compartmentalized because eosinophils as a percentage of all
leukocytes in BAL showed no correlation with results in blood or
in sputum (data not shown). These data extend 2 previous studies
that used cytospin differential counts to enumerate BAL eosin-
ophils. Both found, as we did, that induced sputum results neither
differed between groups nor correlated with BAL percentages.8,9
Our results are also congruent with those ofWen et al,9 who found
increased BAL eosinophils in current smokers with COPD, rela-
tive to ex-smokers with COPD.9
Strengths of our study include its size, inclusion of extensively
phenotyped subjects at multiple clinical centers, and rigorous
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